[PDF][PDF] Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) …
GW Robinson, AJ Gajjar, KM Gauvain, EM Basu… - J Clin …, 2019 - medically.roche.com
GW Robinson, AJ Gajjar, KM Gauvain, EM Basu, ME Macy, LD Maese, AJ Sabnis, JH Foster…
J Clin Oncol, 2019•medically.roche.com… • while rare, this list is growing as mutations and fusions are detectable with next-generation
sequencing • Here, we report on the activity of entrectinib in children with recurrent or
refractory solid tumors including primary CNS tumors … • Entrectinib was generally well
tolerated; the recommended dose of the clinical trial formulation in children is 550 mg/m2
daily … • Entrectinib has very promising anti-tumor activity and PFS in patients with target
gene fusions, especially malignant CNS tumors …
sequencing • Here, we report on the activity of entrectinib in children with recurrent or
refractory solid tumors including primary CNS tumors … • Entrectinib was generally well
tolerated; the recommended dose of the clinical trial formulation in children is 550 mg/m2
daily … • Entrectinib has very promising anti-tumor activity and PFS in patients with target
gene fusions, especially malignant CNS tumors …
Background
ALK, anaplastic lymphoma kinase; CNS, central nervous system; NTRK, neurotrophic tropomyosin receptor kinase; TRKA, tropomyosin receptor kinase A
medically.roche.com
以上显示的是最相近的搜索结果。 查看全部搜索结果